Analysis of clinical patient-specific pre-treatment quality assurance with the new helical tomotherapy platform, following the AAPM TG-218 report

Marco Fusella1, Samuele Cavinato1,2, Alessandra Germani1, Marta Piausco1, Nicola Pivato1, Marco Andrea Rossato1, Anthony Scott3 and Alessandro Scaggion1*

Abstract
Purpose: This study presents patient-specific quality assurance (QA) results from the first 395 clinical cases for the new helical TomoTherapy® platform (Radixact) coupled with dedicated Precision TPS.

Methods: The passing rate of the Gamma Index (GP%) of 395 helical QA of patient-specific tomotherapy, acquired with ArcCHECK, is presented, analysed and correlated to various parameters of the plan. Following TG-218 recommendations, the clinic specific action limit (ALcs) and tolerance limit (TLcs) were calculated for our clinic and monitored during the analysed period.

Results: The mean values (±1 standard deviation) of GP% (3%/2 mm) (both global and local normalization) are: 97.6% and 90.9%, respectively. The proposed ALcs and TLcs, after a period of two years' process monitoring are 89.4% and 91.1% respectively.

Conclusions: The phantom measurements closely match the planned dose distributions, demonstrating that the calculation accuracy of the new Precision TPS and the delivery accuracy of the Radixact unit are adequate, with respect to international guidelines and reports. Furthermore, a first correlation with the planning parameters was made. Action and tolerance limits have been set for the new Radixact Linac.

Keywords: TomoTherapy, Quality assurance, Pre-treatment quality assurance, IMRT QA

Introduction
In early 2018 a new version of the TomoTherapy® platform was commercially released (Radixact, Accuray, Sunnyvale, CA). This new machine is characterized by a higher dose rate of 1000 cGy/min, improved jaw dynamics, faster ring rotation (up to 10 rotations per minute), couch movement with separated axis and a couch catcher to reduce couch sag effect (to less than 2 mm) toward the gantry. The new platform comes with a redesigned version of the TPS: Precision TPS v1.0.02 which incorporates the graphics processing unit (GPU) based optimizer, VoLO™ and a Collapsed Cone Convolution Superposition dose calculation algorithm [1, 2]. This new system grants the capability of faster treatments and more freedom in the combination of the modulation factor, jaw width, pitch and gantry period. Thanks to these advanced features, the use of this system opens to the possibility of achieving more modulated and complex plans.
The long term dosimetric stability of this new delivery system has already been studied and reported by Smilowitz [3] and the new TPS version has been validated by Chen [2]. In order to thoroughly assess the new capability of the system, a detailed and complete analysis on a large database of clinical plans is also needed.

At our department, a Radixact unit machine has become clinical in June 2018 and since the first clinical plan a detailed QA program has been implemented following the recommendations of AAPM TG-218 [4]. Approximately 395 clinical helical plans were delivered and measured with ArcCHECK™ (Sun Nuclear, Melbourne, FL). Measured and calculated dose distributions were compared by means of 2D gamma analysis.

Within this work, we propose the clinic and machine specific tolerance limit (TLcs) and action limit (ALcs), obtained through statistical process control techniques, to be adopted for the new Radixact platform coupled to the Precision TPS v1.0.02. We also analyse and report which planning parameters are more related to QA failures.

Materials and methods

Database

Between June 2018 and October 2020 a total of 395 treatments have been planned with the Precision TPS v1.0.02 using the GPU-based optimizer VoLO™, which incorporates the Collapsed Cone Convolution Superposition dose calculation algorithm [1, 2]. The treatments were related to a large number of different sites and diseases; therefore, within the scope of this work they have been grouped in the following categories: abdomen (28 pts), brain (32 pts), head and neck (77 pts), lungs (71 pts), pelvis (84 pts), prostate (52 pts) and others (41 pts). The dose per fraction (D/fr) ranged from 1.6 to 5 Gy.

Plans characteristics

To characterize the plans, the following parameters were collected: actual modulation factor (MF), pitch, field width (FW), gantry period, total delivery time, couch speed, couch travel distance and TTDF (ratio between the treatment time and the prescribed dose per fraction). Moreover, some descriptors of the leaf open time (LOT) distribution were collected: minimum (min-LOT), mean (mean-LOT), maximum (max-LOT) and LOT standard deviation (SD-LOT). All treatments utilized dynamic jaws [5].

QA delivery and analysis

All the patient-specific QA measurements were collected with ArcCHECK™ (Sun Nuclear, Melbourne, FL) and performed without the 15 cm diameter homogeneous PMMA plug. The plans were recomputed on the synthetic ArcCHECK™ CT provided by the vendor with an imposed density of 1.1836 g/cm³ following manufacturer’s recommendations. Acquisition and analysis were performed with Sun Nuclear SNC Patient™ version 6.7. The absolute dose calibration of ArcCHECK™ was periodically controlled against a calibrated farmer-type ionisation chamber. Before each measurement session, the output of the Radixact unit was checked using the cheese phantom and ionization chambers, and a correction applied to the ArcCHECK™ analysis. QA plans were computed in high resolution mode which grants a 1.87 mm spaced dose grid.

The QA plan was computed placing the centre of the planning PTV at the machine’s isocenter. This procedure reduces the possibility for high dose areas to fall at the border of the ArcCHECK™ limiting the dependence of the gamma passing rate (GP%) on the maximum calculated dose [6].

According to the AAPM TG-218 report, the dose comparison was performed through 2D gamma analysis using a 10% dose threshold as well as 3% dose difference (DD) and 2 mm distance-to-agreement (DTA) criteria. In order to compare our results with previous works [5–8], 3%/3 mm gamma analysis was also collected. Both local and global normalizations were used.

QA program

Following the AAPM TG-218 report, the clinical deliverability of a plan was evaluated on the basis of the universal tolerance limit (TL) and action limit (AL), which are 95% and 90% respectively, on the GP% computed with (3%, 2 mm), global normalization criteria.

Statistical process control techniques recommended in TG-218 have been employed to define a clinic specific TLcs and ALcs [4] as follows:

\[
ALcs = 100 - 3\sqrt{\sigma^2 + (\bar{x} - 100)^2}
\]

\[
TLcs = \bar{x} - 2.660mR
\]

where \(\bar{x}\) is the GP% average over the investigation period, \(\sigma\) is its standard deviation and \(mR\) the moving average. These values were computed on the first 40 collected measurements. The IMRT treatment process has been monitored and investigated by periodically computing these values to verify whether the process was under control. For the subsequent evaluations, periods of approximately 6 months were considered. Only clinically deliverable plans, those fulfilling GP% (3%G, 2 mm) > 90%, were considered in this analysis and 95% confidence intervals on TLcs and ALcs have been computed through a bootstrap approach with 10,000 samples [9, 10].
Statistical analysis

To spot possible differences of GP% among the different treatment sites a Kruskal-Wallis test was performed followed by a post-hoc analysis where Bonferroni correction was applied [11].

N-way analysis of variance (n-way ANOVA) was performed to spot the influence of the planning parameters on GP% [12]. Only parameters that strictly bore no correlations among themselves were included in the test ($p > 0.05$ and/or Pearson’s r < 0.8) [13, 14].

All tests were performed using MATLAB® R2020b (MathWorks, Inc., Natick, MA, USA). All the $p$-values reported are two-sided and $p < 0.05$ is considered as statistically significant.

Results

Over the entire collection period, only 10 out of 385 plans failed to meet the universal AL defined by the TG-218 report. These failing plans were re-planned to meet the universal AL and added to the original set, thus resulting in a total of 395 plans that were actually measured. Figure 1 depicts the whole population of collected QA results.

The measured 3%/2 mm GP% (both global and local normalizations) of the whole population ($n = 395$) was distinguished among treatment sites and the information is presented in Fig. 2. Data include both clinically and non-clinically (GP% (3%G, 2 mm) < 90%) delivered plans. The Kruskal-Wallis test confirmed that some differences among the groups does exist ($p$-value < 0.001). The post-hoc test showed that these differences are statistically significant only when the pelvis plans are compared to abdomen, lungs and others groups.

Table 1 reports the distribution of the collected planning parameters for our database of plans.

![Fig. 1 Violin plot of the complete database of collected measurements distinguished among the different gamma analysis criteria. The central white dot marks the median, the edges of the box correspond to the 25th and 75th percentiles, the whiskers extend to the adjacent values which are the most extreme data values that are not outliers, and data outside the whiskers are outliers. L stands for local gamma normalization, G for global one](image)

![Fig. 2 Whiskers box plot of GP% (3%, 2 mm) (global and local normalizations) of all measured plans distinguished among the different treatment sites. The central line marks the median, the edges of the box are the 25th and 75th percentiles, the whiskers extend to the adjacent values, which are the most extreme data values that are not outliers, and the circles represent the outliers](image)

|   | Average ± SD | Range [min; max] |
|---|--------------|------------------|
| Dose/Fraction [cGy] | 219.8±62.6 | [160.0; 500.0] |
| MF | 1.68±0.28 | [1.10; 2.79] |
| Pitch | 0.39±0.06 | [0.12; 0.48] |
| Gantry Period [s] | 201.7±7.3 | [118; 528] |
| Total Treatment Time [s] | 299.7±141.0 | [66.3; 1241.3] |
| TTDF [s/cGy] | 1.41±0.69 | [0.36; 5.43] |
| min-LOT [ms] | 18.2±1.1 | [18.0; 36.4] |
| mean-LOT [ms] | 236.3±82.7 | [57.8; 617.1] |
| max-LOT [ms] | 391.4±144.0 | [123.2; 1034.2] |
| SD-LOT [ms] | 107.9±44.2 | [21.1; 316.1] |
| Couch speed [mm/s] | 0.56±0.20 | [0.11; 1.84] |
| Couch travel distance [mm] | 160.2±88.9 | [31.1; 895.2] |
| FW (10 mm/25 mm/50 mm) | 2.1%/92.0%/5.9% | |
Figure 3 reports the periodical evaluation of the ALcs and TLcs non-clinical plans are not included. The first 40 plans used for the first calculations (as proposed in TG-218), are also included in period “1”.

Among the first 40 planned treatments, the calculated ALcs and TLcs are, respectively, 93.2% and 93.7%, with all the plans satisfying GP% (3%/2 mm) > 93.3%. The final computation of ALcs and TLcs on the last set of 78 clinical plans yielded ALcs = 89.4% and TLcs = 91.1%.

A Kruskal-Wallis test has been performed to compare ALcs and TLcs samples of period 2, 3 and 4 and no statistically significant differences exist. In these three periods not even a single plan lies below the estimated ALcs, following the recommendations of TG-218, these evidences allow to state that the process is settled and under control. Using data from these 3 periods a n-way ANOVA was performed to detect which parameters might predict QA failures are summarized for both local and global normalizations of GP% with 3%/2mm criteria. Results are given in Table 2.

In Table 2, the results of the n-way ANOVA performed on ALcs and TLcs samples of period 2, 3 and 4 and no statistically significant differences exist. In these three periods not even a single plan lies below the estimated ALcs, following the recommendations of TG-218, these evidences allow to state that the process is settled and under control. Using data from these 3 periods a n-way ANOVA was performed to detect which parameters might predict QA failures are summarized for both local and global normalizations of GP% with 3%/2mm criteria. Results are given in Table 2.

The analysis has been conducted for the data of the last three periods, where the process seems to become settled and under control (Fig. 3).

**Discussion**

In this work, we assessed the performances of the TomoTherapy® platform coupled with a new dedicated TPS in terms of the gamma index passing rate measured with a 3D dosimeter, extending the analysis of previous works on earlier versions of TomoTherapy® and associated TPS [7, 8]. The entire scope of work was performed following AAPM TG-218 recommendations. We considered the GP% metric with 3%/2 mm criteria, analysing also the impact of local and global normalizations. Our results showed that the mean GP% (3%/G/2 mm) was 97.6 ± 2.6% with some differences arising among the different sites used to stratify the sample.

Any previous study on the TomoTherapy® unit has not reported results using the GP% metric defined by AAPM TG-218. For a comparison with existing literature we used the GP% with 3%/3mm criteria. The results here reportedly outperformed those obtained with different versions of tomotherapy machines and the same 3D dosimeter (ArcCHECK™) in terms of GP%. We measured systematically higher mean values with respect to Brescia [7], Binny [15] and Yue [16]: 99.2% (SD 1.3%) vs. 96.1% (SD 4.4%), 95.9% (SD 2.9%) and 97.5% (SD 2.7%), respectively.

Applying the statistical process control techniques proposed by the Task Group, we periodically computed the centre-specific action level and tolerance limit (see Fig. 3). The first evaluation yielded values comparable to the universal ones indicated in the report (93.7% and 93.2%, versus 95% and 90% respectively). The periodical evaluation of the two control limits showed that a change occurred in the process between the first and the second re-evaluation. In fact, both TLcs and ALcs decreased and remained approximately constant afterwards (Fig. 3). This probably happened since the start of 2019 and after six months of initial training, new treatments have been introduced into the clinical practice (e.g. mesotheliomas, craniocerebral irradiations, Hodgkin’s and non-Hodgkin’s lymphomas) that can be considered as inherently more complex; moreover, moving up the learning curve, the planners have begun to achieve increasingly complex and modulated dose distribution; thus probably inducing a decrease of treatment deliverability. All

**Table 2** Results of the n-way ANOVA test on GP% (3%, 2 mm) with respect to all the collected planning parameters in terms of p-values

| Parameter       | (3%L, 2 mm) | (3%G, 2 mm) |
|-----------------|-------------|-------------|
| Site            | 0.002       | 0.063       |
| MF              | 0.294       | 0.199       |
| TTDF            | 0.007       | 0.373       |
| mean-LOT        | 0.642       | 0.437       |
| max-LOT         | 0.804       | 0.859       |
| Pitch           | 0.884       | 0.659       |
| Gantry period   | 0.820       | 0.841       |
| Couch speed     | 0.189       | 0.055       |

Underlined values mark significant tests
this sources of variation forced to follow TG-218 recommend-
ations, going through a periodically monitoring
of the process, investigating the GP% over a long
period.

To spot possible planning parameters closely related
to QA results, and their trend, a n-way ANOVA test
was performed (see Table 2). Only the treatment site
and the TTDF (treatment time divided by the pre-
scribed dose per fraction) were highlighted as possible
predictors of QA failures, only when GP% (3%L, 2mm)
is considered. In fact, the TTDF can be considered as
a simple indicator of complexity, since it is somehow
related to the longitudinal extension of the target vol-
ume and to the pitch. A similar behaviour was recently
reported by Santos et al. [17].

Previous studies reported the effect of mean-LOT,
max-LOT, MF, pitch and gantry period on plan deliv-
erability [6, 7, 15, 18]. In our database, none of the col-
clected parameter can be considered relevant when the
GP% (3%G, 2 mm) is used, and this might be due to
different reasons. First of all, the presence of the TTDF
might mask all the other parameters, since mathemati-
cal relationships hold between the TTDF and most of
the aforementioned parameters. Secondly, our plan-
ning practice strictly follows the recommendation of
the Accuray planning manual [1] which suggests to
prepare plans with max-LOT higher than 241 ms, and
mean-LOT higher than 100 ms. Moreover, approxi-
ately 95% of our plans show the MF within 1.4 and
2.5, which Binny et al. [18] have previously shown to
be associated to acceptable deliverability.

Because no dependence from anatomical site has
been found for GP% (3%G/2 mm), it is possible to
use for all treatments the same ALC and TLG here
reported. When the more stringent local criteria is
considered a significant difference among the anatom-
ical site arouse. In this case group-specific ALC and
TLG would have been required and, following AAPM
TG-218 recommendation, should be computed.

The assessment of the TPS’s performances in regards
to complexity of the calculated sinograms is beyond
the scope of this work, as well as the detailed analy-
sis of the relationship between GP% and clinically rel-
levant deviations [6, 19–21]. A more detailed analysis
on the predictive value of the analysed parameters on
QA trend and failures is still ongoing.

The results of this study highlight the capability of
the Radixact system to accurately deliver complex dose
distributions over a large variety of treatment sites. We
set the TL and AL for this new machine to be used as
reference or comparison for other centres.

Conclusions
The results presented in this study suggest that the calcu-
lation accuracy of the new Precision TPS and the delivery
accuracy of the Radixact unit is adequate, with respect
to international guidelines and reports. Following the
TG-218 methodology, we calculated both tolerance and
action limits for the determination of the clinical deliv-
erability of plans calculated with the new TPS, Accuray
Precision, for the new TomoTherapy® version, (Radixact).
These values have been monitored over a long period,
and can be used as reference or comparison for other
centres implementing this new technology.

Abbreviations
AL: Action limit; ALC: Center specific action limit; CT: Computed tomography;
DO: Dose difference; DTA: Distance-to-agreement; FW: Field width; GP%: Gamma-analysis passing rate; LOT: Leaf open time; MF: Actual modulation
factor; PTV: Planning target volume; QA: Quality assurance; TG: Task group; TL: Tolerance limit; TLC: Center specific tolerance limit; TPS: Treatment planning
system; TTDF: Treatment time over dose per fraction.

Acknowledgements
Not applicable.

Authors’ contributions
All the listed authors have contributed to the work, and approved the manu-
script for submission. AS and MF take care of preparing the manuscript, SC
take care of statistical analysis and figure composition.

Authors’ information
Dr. Marco Fusella, acting as first author of this manuscript acknowledges
the following: He did not receive payment or services from a third party
(government, commercial, private foundation, etc.) for any aspect of the
submitted work. He did not have any financial relationships, during the 36
months prior to submission, a part from the presenting institution. He does
not have any patents, whether planned, pending or issued, broadly relevant to
the presented work. There are no other relationships or activities that readers
could perceive to have influenced, or that give the appearance of potentially
influencing, what he wrote in the submitted work. Based on the above disclo-
sures Dr. Marco Fusella has nothing to disclose.

Dr. Alessandro Scaggion, acting as corresponding author of this manuscript
acknowledges the following: He did not receive payment or services from a
third party (government, commercial, private foundation, etc.) for any aspect of
the submitted work. He did not have any financial relationships, during the 36
months prior to submission, a part from the presenting institution. He does
not have any patents, whether planned, pending or issued, broadly relevant to
the presented work. There are no other relationships or activities that readers
could perceive to have influenced, or that give the appearance of potentially
influencing, what he wrote in the submitted work. Based on the above disclo-
sures Dr. Alessandro Scaggion has nothing to disclose.

Dr. Samuele Cavinato, acting as contributing author of this manuscript
acknowledges the following: He did not receive payment or services from a
third party (government, commercial, private foundation, etc.) for any aspect of
the submitted work. He did not have any financial relationships, during the 36
months prior to submission, a part from the presenting institution. He does
not have any patents, whether planned, pending or issued, broadly relevant to
the presented work. There are no other relationships or activities that readers
could perceive to have influenced, or that give the appearance of potentially
influencing, what he wrote in the submitted work. Based on the above disclo-
sures Dr. Samuele Cavinato has nothing to disclose.

RTT Alessandra Germani, acting as contributing author of this manuscript
acknowledges the following: He did not receive payment or services from a
third party (government, commercial, private foundation, etc.) for any aspect of
the submitted work. He did not have any financial relationships, during the 36
months prior to submission, a part from the presenting institution. He does

not have any patents, whether planned, pending or issued, broadly relevant to the presented work. There are no other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what he wrote in the submitted work. Based on the above disclosures Dr. Marta Pausco has nothing to disclose.

Dr. Marta Pausco, acting as contributing author of this manuscript acknowledges the following. He did not receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work. He did not have any financial relationships, during the 36 months prior to submission, a part from the presenting institution. He does not have any patents, whether planned, pending or issued, broadly relevant to the presented work. There are no other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what he wrote in the submitted work. Based on the above disclosures Dr. Marta Pausco has nothing to disclose.

RTT Nicola Pivato, acting as contributing author of this manuscript acknowledges the following. He did not receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work. He did not have any financial relationships, during the 36 months prior to submission, a part from the presenting institution. He does not have any patents, whether planned, pending or issued, broadly relevant to the presented work. There are no other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what he wrote in the submitted work. Based on the above disclosures RTT Nicola Pivato has nothing to disclose.

RTT Marco Andrea Rossato, acting as contributing author of this manuscript acknowledges the following. He did not receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work. He did not have any financial relationships, during the 36 months prior to submission, a part from the presenting institution. He does not have any patents, whether planned, pending or issued, broadly relevant to the presented work. There are no other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what he wrote in the submitted work. Based on the above disclosures RTT Marco Andrea Rossatto has nothing to disclose.

Dr. Anthony Scott, acting as contributing author of this manuscript acknowledges the following. He did not receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work. He did not have any financial relationships, during the 36 months prior to submission, a part from the presenting institution. He does not have any patents, whether planned, pending or issued, broadly relevant to the presented work. There are no other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what he wrote in the submitted work. Based on the above disclosures Dr. Anthony Scott has nothing to disclose.

Funding
No payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work was received by any of the authors.

Availability of data and materials
Not applicable.

 declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors do not have any competing interests.

Author details
1 Medical Physics Department, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128 Padova, Italy. 2 Dipartimento di Fisica e Astronomia ‘G. Galilei’, Università degli Studi di Padova, Padova, Italy. 3 The Abdus Salam International Centre for Theoretical Physics, Strada Costiera 11, 34151 Trieste, Italy.

Received: 22 September 2021 Accepted: 11 November 2021

References

1. Radixact Physics Essential Guide 1060900-ENG A, Accuray, Version 1.1.x, Date of Revision: 2018-01-02.
2. Chen Q, Lu W, Chen Y, Chen M, Henderson D, Sterpin E. Validation of GPU based TomoTherapy dose calculation engine: TomoTherapy GPU dose validation. Med Phys 2012; 39:1877–86. https://doi.org/10.1118/1.3693057.
3. Smilowitz JB, Dunkley D, Hill PM, Yadav P, Geurts MW. Long-term dosimetric stability of multiple TomoTherapy delivery systems. J Appl Clin Med Phys 2017; 18:137–43. https://doi.org/10.1002/acm2.12085.
4. Mitten M, Olch A, Mikhailidis D, Moran J, Pawlicki T, Molinuev A, et al. Tolerance limits and methodologies for IMRT measurement-based verification QA: recommendations of AAPM Task Group No. 218. Med Phys. 2018;45:e53-83. https://doi.org/10.1002/mp.12810.
5. Sterzing F, Ulh M, Hauswold H, Schubert K, Soroka-Perez G, Chen Y, et al. Dynamic Jaws and dynamic couch in helical tomotherapy. Int J Radiat Oncol Biol Phys. 2010;76:1266–73. https://doi.org/10.1016/j.ijrobp.2009.07.1686.
6. Bresciani S, Dia AD, Maggio A, Cutia C, Miranti A, Infusino E, et al. Tomotherapy treatment plan quality assurance: the impact of applied criteria on passing rate in gamma index method: gamma passing rate variability. Med Phys. 2013;40:121711. https://doi.org/10.1118/1.4829513.
7. Bresciani S, Miranti A, Di Dì A, Maggio A, Bracco C, Poli M, et al. A pretreatment quality assurance survey on 384 patients treated with helical intensity-modulated radiotherapy. Radiother Oncol. 2016;118:574–6. https://doi.org/10.1016/j.radonc.2015.12.021.
8. Geurts M, Gonzalez J, Serrano-Ojeda P. Longitudinal study using a diode phantom for helical tomotherapy IMRT QA: longitudinal study for helical tomotherapy IMRT QA. Med Phys. 2009;36:4977–83. https://doi.org/10.1118/1.3281513.
9. DiCiccio Thomas J, Bradley Efron. Bootstrap confidence intervals. Stat Sci. 1996;11(3):189–228.
10. Jung K, et al. Comparison of bootstrap confidence interval methods for GSCA using a Monte Carlo simulation. Front Psychol. 2019;10:2215. https://doi.org/10.3389/fpsyg.2019.02215.
11. Krukskal William H, Allen Walls W. Use of ranks in one-criterion variance analysis. J Am Stat Assoc. 1952;47(260):583–621.
12. Dunn OJ, Clark VA. Applied Statistics: Analysis of Variance and Regression. New York: Wiley, 1974.
13. Jarpakdee J, Tantithamthavorn C, Hassan AE. The Impact of Correlated Metrics on the Interpretation of Defect Models. in IEEE Transactions on Software Engineering, vol. 47, no. 2, pp. 320-331. https://doi.org/10.1109/TSE.2019.2891758.
14. Kuhn M, Johnson K. Applied predictive modeling, vol. 26. New York: Springer, 2013.
15. Binny D, Lancaster CM, Byrne M, Kairn T, V. Trapp J, Crowe SB. Tomotherapy treatment site specific planning using statistical process control. Physica Medica 2018; 53:32–9. https://doi.org/10.1016/j.physmed.2018.08.003.
16. Yue Q, Duan J, Li R, Yang J. Systematic analysis of the ArcCheck diode arrays for Tomotherapy delivery verification. JUMPCERO. 2014;03:218–25. https://doi.org/10.4236/jmpcero.2014.34028.
17. Santos T, Ventura T, Mateus J, Capela M, do Carmo Lopes M. On the complexity of helical tomotherapy treatment plans. JACMP 2020; 21:107–118. https://doi.org/10.1002/acm2.12985.
18. Binny D, Lancaster CM, Harris S, Sylvander SR. Effects of changing modulation and pitch parameters on tomotherapy delivery quality assurance plans. J Appl Clin Med Phys. 2015;16:87–105. https://doi.org/10.1118/1.4952628.
19. Nelms BE, Zhen H, Tomé WA. Per-beam, planar IMRT QA passing rates do not predict clinically relevant patient dose errors: predicative power of conventional IMRT QA. Med Phys. 2011;38:1037–44. https://doi.org/10.1118/1.3546657.
20. Hussein M, Adams EJ, Jordan TJ, Clark CH, Nisbet A. A critical evaluation of the PTW 2D-ARRAY seven29 and OCTAVIUS II phantom for IMRT and VMAT verification. J Appl Clin Med Phys. 2013;14:274–92. https://doi.org/10.1120/jacmp.v14i6.4460.

21. Stasi M, Bresciani S, Miranti A, Maggio A, Sapino V, Gabriele P. Pretreatment patient-specific IMRT quality assurance: a correlation study between gamma index and patient clinical dose volume histogram. Med Phys. 2012;39:7626–34. https://doi.org/10.1118/1.4767763.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions